Blog | BioInformant

American Academy of Stem Cell Physicians To Hold Board Examination on June 18, 2022, at 2pm

June 7, 2022 By Cade Hildreth, Founder & President Leave a Comment

American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications this June 18, 2022, in Miami!

MIAMI, June 6, 2022 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]

Cord Blood Market Segmentation in 2022

June 2, 2022 By Cade Hildreth, Founder & President Leave a Comment

Cord blood market segmentation is one of the most important (and least appreciated) parts of analyzing the cord blood banking industry. As the first and only market research firm to track the stem cell industry, BioInformant has collected over 16 years of historical information on the cord blood industry from 2006 to present. This provides a powerful record if past industry dynamics, as well as a robust platform for making future projections. [Read more…]

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

May 16, 2022 By Cade Hildreth, Founder & President 1 Comment

SALT LAKE CITY, May 13, 2022 –PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND. [Read more…]

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

May 12, 2022 By Cade Hildreth, Founder & President Leave a Comment

PALO ALTO, Calif., May 11, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up in the field of GMP cell manufacturing CDMO, announced that the company, in collaboration with Genequest Inc., a Tokyo-based direct-to-consumer genetic testing service provider, established a data-driven method to identify potential cell donors with specific haplotypes. With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs. [Read more…]

Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

May 8, 2022 By Cade Hildreth, Founder & President Leave a Comment

HONG KONG, April 29, 2022 — Global Cord Blood Corporation (NYSE: CO, “GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% of Cellenkos, Inc (“CLNK”) and the rights to develop and commercialize all of its existing and future products worldwide except those related to CLNK’s existing collaboration with Incyte Corporation (Nasdaq: INCY, “Incyte”). [Read more…]